Vyvanse (Lisdexamfetamine) in Adults 65 and Older: Geriatric Dosing, Risks, and Transition to Adult Care

Why Geriatric Vyvanse Prescribing Demands a Different Approach

Older adults are underdiagnosed and undertreated for ADHD. Population modelling suggests that roughly 2 to 4% of adults over 60 meet DSM-5 criteria for ADHD, yet prescription rates in that cohort remain a fraction of those in adults aged 18 to 44. [1] Several patients now entering their mid-60s have been on stimulant therapy continuously since young adulthood, which creates a clinical transition problem: the prescriber who managed their care for decades may no longer be the right fit for a patient whose physiology, comorbidities, and polypharmacy have shifted substantially.

Vyvanse is a prodrug. Orally ingested lisdexamfetamine is cleaved by erythrocyte peptidases to release d-amphetamine and l-lysine. [2] The prodrug design was intended to reduce abuse liability compared to immediate-release amphetamine salts. In younger adults, this mechanism produces a smooth, extended peak plasma concentration of d-amphetamine at roughly 3.8 hours post-dose. In adults 65 and older, that curve may be altered by reduced renal tubular secretion of d-amphetamine, lower plasma volume, and age-related changes in body composition that affect volume of distribution.

The FDA label for Vyvanse does not contain a specific geriatric dosing section, noting only the general principle that older adults may be more sensitive to sympathomimetic effects. [3] That silence places the clinical burden squarely on the prescriber.

The Demographics Are Shifting

The U.S. Population aged 65 and older is projected to reach 82 million by 2050, according to the U.S. Census Bureau. [4] Within that group, a growing cohort carries a long-standing ADHD diagnosis. Some were diagnosed in childhood under older DSM-III or DSM-IV criteria. Others received diagnoses in their 30s or 40s after decades of misdiagnosis as anxiety or mood disorders. A third group, smaller but notable, is newly diagnosed in their 60s after retirement removes the compensatory structures (work deadlines, assistants, structured schedules) that masked symptoms for years.

Each of these patient pathways arrives at geriatric care with different medication histories. The newly diagnosed patient starts fresh and benefits from conservative titration. The patient who has taken Vyvanse 50 mg daily for 15 years presents a more complex case: discontinuing a stable, effective regimen carries its own risks, including executive function decline that may accelerate cognitive aging trajectories. [5]

Evidence Gaps in This Population

All three key Phase 3 registration trials that supported Vyvanse's FDA approval for ADHD enrolled adults between 18 and 55 years old. The SPD489-325 study (N=420) and the related SPD489-326 study (N=414) both capped enrollment at age 55. [6] Adults 65 and older were not represented. Clinicians therefore extrapolate efficacy and titration guidance from younger adult data, a practice that is common but carries meaningful uncertainty.

Pharmacokinetics in Older Adults: What Changes After 65

Age changes the body in ways that affect every stimulant pharmacokinetic parameter. Knowing which changes matter most for lisdexamfetamine guides rational dose selection.

Renal Clearance

D-Amphetamine is renally eliminated. Approximately 30 to 40% of a dose is excreted unchanged in urine, and the rest is excreted as amphetamine metabolites. [3] Renal function declines with age: mean GFR falls approximately 1 mL/min/1.73 m² per year after age 40, so a healthy 68-year-old may have an eGFR of 60 to 70 mL/min/1.73 m² even without overt kidney disease. [7] This slower clearance extends the half-life of d-amphetamine and raises trough plasma concentrations, effectively meaning a 30 mg dose in a 68-year-old may produce drug exposure closer to a 40 mg dose in a 35-year-old.

The FDA label addresses this directly. Maximum daily dose in severe renal impairment (eGFR <15 mL/min/1.73 m²) is capped at 50 mg/day, and in end-stage renal disease requiring dialysis, the cap is 30 mg/day. [3] For the large number of geriatric patients with moderate impairment (eGFR 30 to 59), no specific dose cap exists in labeling, but cautious titration and renal function monitoring are warranted.

Body Composition and Volume of Distribution

Older adults have less skeletal muscle and proportionally more adipose tissue. Amphetamine is a basic lipophilic drug with a volume of distribution of approximately 3.5 to 4.6 L/kg in young adults. Age-related shifts in lean-to-fat ratio may subtly increase distribution volume, which could theoretically offset some of the prolonged half-life from reduced renal clearance. However, this effect is generally considered smaller than the renal clearance effect in clinical practice.

Hepatic Metabolism

The peptidase cleavage of lisdexamfetamine to d-amphetamine occurs primarily in red blood cells, not the liver. Age-related reductions in hepatic cytochrome P450 activity therefore affect downstream amphetamine metabolism only modestly. This is one pharmacokinetic advantage of the prodrug structure for older populations.

Drug-Drug Interactions in a Polypharmacy Context

Patients 65 and older take an average of 4 to 5 prescription medications. [8] Several drug classes common in this age group interact directly with lisdexamfetamine:

• Monoamine oxidase inhibitors (MAOIs): contraindicated within 14 days due to hypertensive crisis risk.
• Proton pump inhibitors and urinary alkalinizing agents (sodium bicarbonate, acetazolamide): raise urinary pH, reduce amphetamine ionization, increase renal reabsorption, and raise plasma d-amphetamine by up to 50%. [3]
• Antihypertensives: amphetamine-mediated catecholamine release may blunt the efficacy of beta-blockers, alpha-blockers, and some calcium channel blockers.
• SSRIs and SNRIs: serotonergic effects are additive; the combination is not contraindicated but warrants monitoring for agitation, autonomic instability, or serotonin syndrome features in high-risk patients.

A medication reconciliation review is non-negotiable before initiating or continuing Vyvanse in any patient over 65.

Cardiovascular Risk Assessment: The Central Safety Concern

Cardiovascular risk is the most consequential safety domain when prescribing Vyvanse to older adults. The prevalence of hypertension in adults 65 and older exceeds 70%. [9] Coronary artery disease, arrhythmias including atrial fibrillation, and heart failure all increase sharply in this cohort.

What the Clinical Trial Data Show

The Vyvanse prescribing information reports mean increases of approximately 2 to 4 mmHg in systolic blood pressure and 3 to 6 beats per minute in resting heart rate across adult clinical trial populations. [3] These modest mean changes obscure individual variability: some patients experience 10 to 15 mmHg systolic rises, particularly at higher doses.

A 2023 retrospective cohort study published in JAMA Network Open (N=278,027 adults prescribed stimulants) found that current stimulant use was associated with a 36% higher incidence of cardiovascular events compared with non-use (adjusted hazard ratio 1.36, 95% CI 1.25 to 1.48). [10] The association was stronger in adults over 60 than in younger age groups.

Absolute Contraindications and High-Risk Conditions

The FDA labels advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, and known hypersensitivity to amphetamine products as contraindications. [3] In a geriatric population, many patients carry at least one of these conditions. Pre-prescription cardiovascular evaluation should include:

1. Resting blood pressure and heart rate (two readings, 5 minutes apart)
2. 12-lead ECG to assess for QT prolongation, bundle branch block, or pre-existing arrhythmia
3. Inquiry about chest pain, palpitations, syncope, or exertional dyspnea
4. Review of prior cardiac imaging if available

Patients with a history of structural heart disease, recent myocardial infarction (within 6 months), or uncontrolled hypertension (systolic above 160 mmHg despite treatment) should not receive Vyvanse until those conditions are addressed. Cardiology co-management is appropriate for borderline cases.

Monitoring Protocol After Initiation

Blood pressure and heart rate should be checked at every clinical contact for the first 3 months. After stabilization, quarterly monitoring is reasonable. A rise of more than 10 mmHg systolic or a resting heart rate above 100 bpm at any point warrants dose reduction or, depending on severity, discontinuation.

Transition to Adult Care: The Structural Problem

The phrase "transition to adult care" typically refers to adolescents moving from pediatric to adult medicine. For ADHD and Vyvanse specifically, the term now applies to a second transition: patients who have been managed in general adult psychiatry or by a single longtime prescriber (often in their 40s or 50s as a clinician) and who now require geriatric psychiatry or geriatric medicine involvement.

There is no federally mandated or professional-society-endorsed transition protocol specifically for ADHD patients aging into geriatric care. The American Academy of Child and Adolescent Psychiatry (AACAP) publishes transition guidelines for adolescents, but those documents end at age 26. [11] The American Association for Geriatric Psychiatry has not published a Vyvanse-specific or stimulant-specific transition standard as of the date of this article's review.

A Practical Transition Framework for Clinicians

The following framework synthesizes FDA labeling guidance, published pharmacokinetic data, and geriatric prescribing principles into a structured hand-off process. Clinicians managing a patient turning 65 who is currently stable on Vyvanse should consider the following steps:

Step 1: Comprehensive medication reconciliation. At the 64-year visit, audit all current medications, supplements, and over-the-counter drugs for interactions. Identify and document any changes in renal function (obtain eGFR), cardiac history, or sleep architecture over the prior 12 months.

Step 2: Cardiovascular clearance. Obtain a baseline ECG and current blood pressure readings. If hypertension is newly identified or worsening, stabilize it before continuing stimulant therapy.

Step 3: Dose rationalization. Review whether the current dose remains necessary and appropriate. Many patients find that a 10 to 20 mg dose reduction at age 65 maintains therapeutic effect while reducing cardiovascular load, owing to the pharmacokinetic changes in renal clearance described above.

Step 4: Prescriber hand-off documentation. The transferring clinician should provide a written summary covering: diagnosis basis, duration of therapy, all dose changes over time, adverse events, psychiatric comorbidities, and the reason the current dose was selected. Verbal hand-offs alone are insufficient given the Schedule II status of the medication.

Step 5: New prescriber orientation visit. The receiving clinician (geriatric psychiatrist, geriatric medicine specialist, or experienced adult psychiatrist) should conduct an independent functional assessment using validated tools. The Adult ADHD Self-Report Scale (ASRS v1.1) provides a brief structured measure appropriate for this transition. [12]

Step 6: Periodic re-evaluation of diagnosis. ADHD symptoms overlap considerably with early cognitive decline, hypothyroidism, obstructive sleep apnea, and depression, conditions that increase in prevalence after 65. At the transition visit and annually thereafter, clinicians should actively exclude these conditions rather than assuming that a long-standing ADHD diagnosis remains the primary driver of symptoms.

When to Consider Discontinuation

Discontinuation of long-term Vyvanse therapy is appropriate in geriatric patients when any of the following occur:

• Development of a new cardiac arrhythmia, particularly atrial fibrillation with rapid ventricular response
• Uncontrolled hypertension despite three antihypertensive agents
• Significant weight loss below a body mass index of 18.5 kg/m² (amphetamines suppress appetite, a real concern in elderly patients at risk for sarcopenia)
• New diagnosis of moderate-to-severe dementia, where the risk-benefit calculation shifts substantially
• Patient preference, especially if functional impairment from ADHD is no longer the primary concern

Abrupt discontinuation after long-term use can precipitate rebound fatigue, dysphoria, and cognitive slowing. A taper over 2 to 4 weeks using 10 mg decrements is generally well tolerated and preferable to stopping cold.

Sleep, Cognition, and Quality of Life Considerations

Sleep architecture deteriorates with age independent of medication effects. Total sleep time shortens, slow-wave sleep decreases, and sleep efficiency falls. Amphetamines are known to delay sleep onset and reduce total sleep time, even when taken in the morning. [13]

Managing Sleep Disruption

For a 65-year-old patient taking Vyvanse 30 mg at 7:00 AM, d-amphetamine plasma concentrations remain measurable 10 to 12 hours later, well into the evening. Patients with baseline insomnia or early-morning awakening may find this intolerable. Practical options include:

• Moving dosing time earlier (6:00 AM with an alarm, before breakfast)
• Dose reduction to the minimum effective dose
• Addition of low-dose melatonin (0.5 to 1 mg) at bedtime, which has a benign safety profile in older adults [14]
• Switching to a shorter-acting amphetamine formulation under specialist guidance, though this trades the abuse-deterrence benefits of the prodrug design

Cognitive Benefits vs. Risks

Several observational studies suggest that appropriately treated ADHD in older adults may reduce the rate of functional cognitive decline compared with untreated ADHD, though randomized controlled trial data specific to this population are absent. [5] The rationale involves chronic prefrontal hypodopaminergia in untreated ADHD accelerating age-related executive function decline. This remains a hypothesis, not established clinical evidence. Clinicians should not use this reasoning to override cardiovascular safety signals.

Dosing Reference for Geriatric Patients

The table below reflects FDA label information combined with conservative geriatric prescribing principles. No geriatric-specific RCT data exist; all recommendations extrapolate from adult data and renal pharmacokinetics.

| Clinical Scenario | Starting Dose | Titration Interval | Practical Maximum | |---|---|---|---| | New start, age 65+, normal renal function (eGFR >60) | 20 mg/day | Increase 10 mg every 2 weeks | 50 mg/day | | Continuing therapy from adult care, stable on established dose | Continue current dose with quarterly monitoring | Reduce by 10 mg if new cardiovascular concern | 70 mg/day (label max) with close monitoring | | Moderate renal impairment (eGFR 30 to 59) | 20 mg/day | Increase 10 mg every 3 weeks | 40 mg/day (clinical conservatism) | | Severe renal impairment (eGFR <15) | 20 mg/day | Increase only after 4 weeks | 50 mg/day (FDA label) | | ESRD on dialysis | 20 mg/day | Caution; minimal data | 30 mg/day (FDA label) |

Regulatory and Prescriptive Considerations

Vyvanse is a Schedule II controlled substance under the Controlled Substances Act. [3] Prescriptions cannot be called in by phone in most states and cannot carry refills. For older adults who may have mobility limitations, transportation difficulties, or cognitive changes that make monthly in-person visits burdensome, this regulatory reality creates a practical access barrier.

As of 2025, the DEA's telehealth prescribing rules for Schedule II stimulants require that a patient have at least one in-person visit with the prescribing clinician before a controlled substance can be prescribed via telemedicine, with limited exceptions for certain clinical scenarios. [15] Clinicians establishing new care with a geriatric patient transitioning from another prescriber should plan for an in-person evaluation regardless of the telehealth capability of their practice.

State prescription drug monitoring programs (PDMPs) must be checked before prescribing or continuing Vyvanse in any patient, per most state laws. This check is especially relevant at the care transition point, where a patient may have overlapping prescriptions during the handoff period.